AR014313A1 - Derivados de benzosulfona, medicamento que los contiene, procedimiento para su preparacion y su empleo para la manufactura de dicho medicamento - Google Patents

Derivados de benzosulfona, medicamento que los contiene, procedimiento para su preparacion y su empleo para la manufactura de dicho medicamento

Info

Publication number
AR014313A1
AR014313A1 ARP990100132A ARP990100132A AR014313A1 AR 014313 A1 AR014313 A1 AR 014313A1 AR P990100132 A ARP990100132 A AR P990100132A AR P990100132 A ARP990100132 A AR P990100132A AR 014313 A1 AR014313 A1 AR 014313A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydrogen
amino
trifluoromethyl
phenyl
Prior art date
Application number
ARP990100132A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR014313A1 publication Critical patent/AR014313A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Derivados de benzosulfona de la formula general (I) en donde R1 es hidrogeno; R2 es hidrogeno, trifluorometilo o alquilo inferior; R3 es hidrogenoo amino; o R1 y R2 o R3 y R2 tomados conjuntamente son -CH=CH-CH=CH; Z es pirimidin-4-ilo, piridin-4-ilo, piridin-2-ilo o fenilo; R4, R5 son cada uno,independientemente, hidrogeno, alquilo inferior, trifluorometilo, halogeno, alcoxilo inferior, nitrilo, amino, alquil-amino inferior, di-alquil-aminoinferior, piperazinilo, morfolinilo,pirrolidinilo, vinilo, cicloalquilo de C3-6, cicloalquenilo de C3-6, t-butiletinilo, hidroxialquiletinilo,feniletinilo, naftilo, tiofenio o fenilo, que puede estar sustituido por halogeno, alcoxilo inferior, alquilo inferior, trifluorometilo, mitro o ungrupo -NH(CH2)nNR6R7, -N(CH3)(CH2)n-morfolin-4-ilo o -NH(CH)nOH; N es 2-4; R6 y R7 son cada uno, independientemente hidrogeno o alquilo inferior. Con lasalvedad de que cuando Z es pirimidin-4-ilo, R4 es diferente de R5, cuando Z espirimidin-2-ilo, R5 no es alquilo inferior y cuando Z es fenilo, R4 y uno deR1-R3 son diferentes de hidrogeno, y a sus sales farmacéuticamente aceptables; medicamento que los contiene, procedimiento para su preparacion y su empleopara la manufactura de dicho medicamento. Se ha encontrado que los compuestos de formlula (I) poseen una afinidad selectiva a los receptores de 5HT-6. Sonpor consiguiente apropiados para el tratamiento o prevencion de trastornos del sistema nervios central tal como, por ejemplo, psicosis, esquizofrenia,depresiones maníacas.
ARP990100132A 1998-01-16 1999-01-15 Derivados de benzosulfona, medicamento que los contiene, procedimiento para su preparacion y su empleo para la manufactura de dicho medicamento AR014313A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98100690 1998-01-16

Publications (1)

Publication Number Publication Date
AR014313A1 true AR014313A1 (es) 2001-02-07

Family

ID=8231273

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100132A AR014313A1 (es) 1998-01-16 1999-01-15 Derivados de benzosulfona, medicamento que los contiene, procedimiento para su preparacion y su empleo para la manufactura de dicho medicamento

Country Status (34)

Country Link
US (1) US5990105A (es)
EP (1) EP0930302B1 (es)
JP (1) JP3249092B2 (es)
KR (1) KR100319250B1 (es)
CN (1) CN1148356C (es)
AR (1) AR014313A1 (es)
AT (1) ATE236136T1 (es)
AU (1) AU757841B2 (es)
BR (1) BR9900065A (es)
CA (1) CA2258454A1 (es)
CO (1) CO5090847A1 (es)
CZ (1) CZ12099A3 (es)
DE (1) DE69906397T2 (es)
DK (1) DK0930302T3 (es)
ES (1) ES2193607T3 (es)
HK (1) HK1022310A1 (es)
HR (1) HRP990011B1 (es)
HU (1) HUP9900120A3 (es)
ID (1) ID23234A (es)
IL (1) IL128027A (es)
MA (1) MA26599A1 (es)
MY (1) MY121778A (es)
NO (1) NO312065B1 (es)
NZ (1) NZ333706A (es)
PE (1) PE20000170A1 (es)
PL (1) PL194735B1 (es)
PT (1) PT930302E (es)
RU (1) RU2201922C2 (es)
SG (1) SG71898A1 (es)
SI (1) SI0930302T1 (es)
TR (1) TR199900090A2 (es)
TW (1) TW553938B (es)
YU (1) YU1199A (es)
ZA (1) ZA99254B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030109B2 (en) 1999-07-19 2006-04-18 Pharmacia & Upjohn Company 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
DE19956791A1 (de) 1999-11-25 2001-05-31 Merck Patent Gmbh Neue Sulfonyloxazolamine
AU2005102A (en) * 2000-11-02 2002-05-15 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
KR100608417B1 (ko) 2001-08-10 2006-08-02 에프. 호프만-라 로슈 아게 5-ht6 수용체 친화성을 갖는 아릴설포닐 유도체
MXPA04003419A (es) 2001-10-09 2004-07-08 Upjohn Co Tetrahidro y hexahidro-carbazoles sustituidos con arilsulfonilo como ligandos del receptor 5-ht-6.
ES2307919T3 (es) * 2002-03-27 2008-12-01 Glaxo Group Limited Derivados de quinolina y su uso como ligandos de 5-ht6.
US6875771B2 (en) 2002-07-26 2005-04-05 Bristol-Myers Squibb Company Pyridopyrimidine derivatives as 5-HT6 antagonists
PL377821A1 (pl) * 2002-11-21 2006-02-20 Chiron Corporation 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
GB0305575D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
GB0419192D0 (en) * 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
PT1831159E (pt) * 2004-12-21 2010-03-03 Hoffmann La Roche Derivados de tetralina e de indano e as suas utilizações
WO2006119390A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007144005A1 (en) 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
JP2010509266A (ja) * 2006-11-09 2010-03-25 エフ.ホフマン−ラ ロシュ アーゲー 5−ht6阻害剤としてのアリールスルホニルピロリジン
JP2010518107A (ja) * 2007-02-06 2010-05-27 ノバルティス アーゲー Pi3−キナーゼ阻害剤およびその使用方法
MX2010003765A (es) * 2007-10-26 2010-04-30 Suven Life Sciences Ltd Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6.
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
RU2443697C1 (ru) 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
CU24269B1 (es) 2011-09-27 2017-08-08 Novartis Ag 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
RU2676277C2 (ru) 2013-01-18 2018-12-27 Кардиоксил Фармасьютикалз, Инк. Доноры нитроксила с улучшенным терапевтическим индексом
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
GB201514021D0 (en) * 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
EP3580203A1 (en) 2017-02-07 2019-12-18 Oblique Therapeutics AB Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
CN110382480A (zh) 2017-02-07 2019-10-25 欧比力克治疗公司 杂环基磺酰基取代的吡啶和其在癌症治疗中的用途
US11208384B2 (en) 2017-02-07 2021-12-28 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55151560A (en) * 1979-05-14 1980-11-26 Ishihara Sangyo Kaisha Ltd Pyridylthioaniline compound
JPS60185764A (ja) * 1984-03-05 1985-09-21 Wako Pure Chem Ind Ltd ピリジン誘導体の新規な製造法
DE4137433A1 (de) * 1990-11-27 1992-06-11 Merck Patent Gmbh 3,6-disubstituierte-2-halogenpyridine
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
JPH06127956A (ja) * 1992-10-16 1994-05-10 Copal Co Ltd ガラスレンズの成形装置
JP3907722B2 (ja) * 1995-08-23 2007-04-18 株式会社クラレ 2−ヒドロキシピリジン類および/または2(1h)−ピリドン類の製造法
JP3907721B2 (ja) * 1995-08-23 2007-04-18 株式会社クラレ 2−アラルキルオキシピリジン類の製造法
EP0894791A4 (en) * 1996-03-29 2001-07-11 Ube Industries PYRIMIDINE COMPOUNDS, PROCESS FOR THE PRODUCTION THEREOF AND BACTERICIDES FOR AGRICULTURE AND HORTICULTURE
JP3814885B2 (ja) * 1996-09-03 2006-08-30 宇部興産株式会社 2−シアノピリミジン誘導体、その製造法及び農園芸用の殺菌剤
US6191280B1 (en) * 1997-05-30 2001-02-20 Basf Aktiengesellschaft Method for producing substituted thiopyridines
KR100396431B1 (ko) * 1998-01-26 2003-09-02 가부시키가이샤 구라레 2-술포닐피리딘 유도체 및 2-[((2-피리딜)메틸)티오]-1h-벤즈이

Also Published As

Publication number Publication date
US5990105A (en) 1999-11-23
BR9900065A (pt) 2000-05-09
CN1148356C (zh) 2004-05-05
ZA99254B (en) 1999-07-16
NO312065B1 (no) 2002-03-11
HUP9900120A3 (en) 2001-02-28
EP0930302A3 (en) 1999-09-01
RU2201922C2 (ru) 2003-04-10
TR199900090A3 (tr) 1999-08-23
ID23234A (id) 2000-03-30
HUP9900120A2 (hu) 1999-11-29
PT930302E (pt) 2003-07-31
DE69906397D1 (de) 2003-05-08
PL330841A1 (en) 1999-07-19
NZ333706A (en) 2000-08-25
JP2000053635A (ja) 2000-02-22
PE20000170A1 (es) 2000-03-29
TR199900090A2 (xx) 1999-08-23
CN1231287A (zh) 1999-10-13
ES2193607T3 (es) 2003-11-01
HRP990011A2 (en) 1999-10-31
HK1022310A1 (en) 2000-08-04
IL128027A0 (en) 1999-11-30
CA2258454A1 (en) 1999-07-16
EP0930302A2 (en) 1999-07-21
HU9900120D0 (en) 1999-03-29
NO990187L (no) 1999-07-19
EP0930302B1 (en) 2003-04-02
ATE236136T1 (de) 2003-04-15
CO5090847A1 (es) 2001-10-30
AU1211099A (en) 1999-08-05
KR100319250B1 (ko) 2002-01-05
CZ12099A3 (cs) 1999-08-11
MA26599A1 (fr) 2004-12-20
NO990187D0 (no) 1999-01-15
IL128027A (en) 2004-03-28
YU1199A (sh) 2002-08-12
SI0930302T1 (en) 2003-10-31
HRP990011B1 (en) 2004-12-31
TW553938B (en) 2003-09-21
SG71898A1 (en) 2000-04-18
DK0930302T3 (da) 2003-07-21
JP3249092B2 (ja) 2002-01-21
MY121778A (en) 2006-02-28
DE69906397T2 (de) 2004-02-19
KR19990067875A (ko) 1999-08-25
AU757841B2 (en) 2003-03-06
PL194735B1 (pl) 2007-06-29

Similar Documents

Publication Publication Date Title
AR014313A1 (es) Derivados de benzosulfona, medicamento que los contiene, procedimiento para su preparacion y su empleo para la manufactura de dicho medicamento
AR019626A1 (es) Antagonistas receptores y5 de neuropeptidos.
GT200100183A (es) Derivados de quinolina y quinazolina.
AR043700A1 (es) Derivados de 3-substituida-4-pirimidona
AR035532A1 (es) Diaminotiazoles, composiciones farmaceuticas que los comprenden, intermediarios para la preparacion de dichos compuestos, uso de dichos compuestos en la preparacion de medicamentos, y procesos para la preparacion de dichos compuestos
AR020590A1 (es) 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
AR032592A1 (es) Aminoalcoxicarbazoles y el uso de los mismos para la manufactura de un medicamento para el tratamiento de enfermedades del snc
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
AR050711A1 (es) Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
PE20212325A1 (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infeccion por vhb o enfermedades inducidas por vhb
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
DE602006019221D1 (de) Von dopamin-d3-rezeptoren
AR015712A1 (es) Derivados de 3,4-dihidro-tieno[2,3-d]pirimidina-3-sustituidos y su uso para la preparacion de composiciones farmaceuticas
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
PE20231097A1 (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso
ES2126773T3 (es) Derivados triciclicos heteroaromaticos condensados como ligandos de subtipos de receptores de dopamina.
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
AR047337A1 (es) Ligandos de los receptores de acetilcolina nicotinicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure